GDP increase from Health Spending: Decreased Discretionary Spending the Result

It’s reported that consumer spending has increased since the 1960’s  from 61% to  71% of the the gross domestic product.  However, most of the increment is health care costs. 

Medical payments now account for about 16 percent of total consumer spending, more than food and clothing combined, which make up about 11 percent, or housing, which accounts for about 15 percent. The rising cost of health care means it will consume an even bigger share of the world’s largest economy as the population ages, according to economists like Jay Feldman.

“At the consumer level, it may squeeze out other discretionary spending,” Feldman, an economist at Credit Suisse in New York, said in an e-mail. “At the government level, rising Medicare and Medicaid spending will inevitably put pressure on other government spending priorities. At the business level, it could curtail investment, or more likely, suppress wages.”

Capture

Medicynical Note:  Increased discretionary consumer spending as a proportion of GDP (over the last 50 years in the U.S.) is an oxymoron.

Health Spending Growth: Regressing or on Hiatus

Uwe Reinhardt has some thoughts on the “moderation” of health spending.  He notes:

First, depending on the beginning and end points one chooses for calculation, the average percentage points by which the annual growth in health spending has exceeded the average annual growth in G.D.P. over the chosen period – a difference known among health policy analysts simply as “excess cost growth” – can vary quite a bit. One really needs charts like these to study the phenomenon, not point-to-point averages.

Second, the annual growth in real health spending per capita appears to have fluctuated around a long-run trend that has declined ever so gently over the longer period (see the blue line in Chart 3). That trend reflects in part that the annual growth in real G.D.P. per capita has also fluctuated around a gently declining trend line. As is shown in Chart 4, the trend line around which excess growth fluctuates is virtually flat.

The graphs show a huge yearly difference in the rate of increase in health care spending.  Read the article to view them.

Medicynical Note:  What’s missing from the article is a comparison of the increase in costs of health care with increases (or lack thereof) in income over the same period.  GDP increments miss entirely the huge disparities in wealth that have evolved in the past 30 years and the resulting poverty, decreases in real income, and decreases in the ability to pay for anything, including health care. 

The dilemma of U.S. health care is seems obvious.  Our costs have exceeded our individual and collective ability to pay.  How to resolve the disparity is the issue.

Two Ruined Lives: Boy 15 shoots sister

A sad but uniquely American happening

The teen likely killed his sister sometime after 8 a.m., when his parents left to go grocery shopping in Fort Smith, about 40 miles away, Boen said. The boy turned himself in at the sheriff’s department about an hour and a half later.

And:

Guns were confiscated from the family’s home and vehicle, the sheriff said. Authorities were trying to determine which weapon was used in the shooting.

Medicynical Note:  More than two lives ruined.  If you must have guns, please keep them locked up.

Great Moments in Medicine: Outpatient shocked by $45 billion dollar hospital bill

Mad Magazine famously pointed out the inflation in medical costs in the late 60’s with a parody on ads by Parke Davis (By Ken Freas). 

image

Parody sadly has become reality:  Outpatient shocked by $45 billion bill.

Malaria: Artemisinin, Antimalarial with a political agenda

Fascinating story of the development of artemisinin, a antimalarial developed in China during the Vietnam era. 

Artemisinin’s discovery is being talked about as a candidate for a Nobel Prize in Medicine. Millions of American taxpayer dollars are spent on it for Africa every year.

But few people realize that in one of the paradoxes of history, the drug was discovered thanks to Mao Zedong, who was acting to help the North Vietnamese in their jungle war against the Americans. Or that it languished for 30 years thanks to China’s isolation and the indifference of Western donors, health agencies and drug companies.

Medicynical Note:  Perversely, the delay in development and distribution prevented it’s wide use, and perhaps the development of resistance.  It remains an effective agent.

Product Line! Bottom Line! The New Paradigm for Medicine—Sleep Apnea

In the past 30 years the diagnosis of sleep apnea has gone from being an oddity to a mainline healthcare business.  Testing and prescribing has become a niche that provides lucrative revenue to specialized businesses.   As noted here:

It’s a condition shown to increase the risk of several serious illnesses, including heart disease, stroke and dementia. Critics, however, worry that overnight tests to diagnose apnea, particularly those done in sleep labs, may be over-prescribed, at great cost to the health care system.

Testing can be a lucrative business, and labs have popped up in free-standing clinics and hospitals across the country. Over the past decade, the number of accredited sleep labs that test for the disorder has quadrupled, according to the American Academy of Sleep Medicine.

At the same time, insurer spending on the procedure has skyrocketed. Medicare payments for sleep testing increased from $62 million in 2001 to $235 million in 2009, according to the Office of the Inspector General.

And:

It’s no secret that the sleep business can be lucrative for physicians. A website for Aviisha, a sleep testing company, has a special page for physicians showing a picture of a doctor with a stack of money in his lab coat pocket. And in February, the American Academy of Sleep Medicine is offering a seminar on the “business of sleep medicine for physicians” at a golf resort in Arizona.

Insurers are catching on and limiting the expensive on site testing encouraging  more use of home testing. 

What’s most interesting about this expenditure is that while there is extensive data showing a short-term improvement in symptoms with treatment there is no long term outcome data documenting effectiveness.  As noted in this presentation by Henry Glick of the University of Pennsylvania from the American Thoracic Society in 2010:

Given the large number of studies, why hasn’t the
question been satisfactorily answered?

  • Shares with health problems such as obesity the fact that while it “makes sense” that treatment should avoid outcomes such as heart attacks and stroke, but no trial has ever demonstrated that treatment actually avoids these outcomes (Medicynical Emphasis)

Medicynical Note:  As noted in a 1999 article on the costs of sleep apnea,

We conclude that patients with undiagnosed sleep apnea had considerably higher medical costs than age and sex matched individuals and that the severity of sleep-disordered breathing was associated with the magnitude of medical costs. Using available data on the prevalence of undiagnosed moderate to severe sleep apnea in middle-aged adults, we estimate that untreated sleep apnea may cause $3.4 billion (probably ten times that amount today) in additional medical costs in the U.S.  Whether medical cost savings occur with treatment of sleep apnea remains to be determined.

Confusing any study of outcomes is the fact that of those treated with CPAP  machines (continues positive pressure) only a minority, perhaps a small minority, continue to use them.

I conclude then, that there is a problem called sleep apnea, caused to a great extent by obesity.   We know, also, that an expensive diagnosis and treatment industry has evolved to manage this problem.  Sleep apnea diagnosis has become a product line for many companies.   There is evidence that  treatments,  some surgical and permanent and others temporary with use of oral appliances and/or machines may (CPAP) improve some symptoms.  But there is no evidence, at this time, that these treatments prevent long term complications (cardiovascular or pulmonary) and death.   For all we know, people treated may have exactly the same outcome as those not treated.

This raising the question of what is a cost effective approach for this problem?  Is our current approach  the most medically effective or do we need to rethink the whole thing?

Health Care Spending Slows (McKinsey)—It’s Economic Rationing?

McKinsey group believes the slowdown in the growth of health care spending is complicated but at least in part driven  by “value” seeking consumers .  They note that consumers are paying a larger proportion of their health care expenses and that makes them more conscious of cost.

Remember we are talking about  a decrease in the rate of increase, not an actual decrease in the amount spent. In fact, our spending per-capita still far exceeds what one would expect even given our wealth when compared with other countries around the world.  This is evidence of an inefficient non-competitive approach. 

The historic slowdown in spending growth was caused by the convergence of a number of factors, including changes in benefit design, structural shifts within specific segments of the health economy, and a recession from which the U.S. economy has been slow to recover. Changes in coverage patterns and the decline in the share of the population with private insurance during the recession have also played an important role. Between 2007 and 2009, the number of people with employer-sponsored or private individual insurance fell by nearly 10 million. In 2009, the share of Americans with private insurance slipped to 64.5 percent – the lowest in 20 years of census records – while the share receiving public assistance and the percent uninsured both reached record highs. 

Despite the “slowdown”  our costs/capita for health care remain by far the highest in world.  For example hospital costs, even with the decreased “utilization:”

costhospitalization

 Medicynical Note:  Mckinsey may view this decreased rate of increase as a search for value in health care, which is laudable. 

However, searching for value when it’s driven by lack of insurance, substandard coverage and poverty  easily morphs into inadequate access, delays, and substandard health care (economic rationing).

No New Polio Cases: India

This report of no new polio cases in India validates (no thinking person really needed further validation) the use of vaccines in serious life-threatening diseases. 

The world of polio as it appeared in 2011:  Countries in black still reporting cases, except perhaps India!

image

Source:  Kaiser Family Foundation

Medicynical Note:  In the early part of my medical career I observed the WHO’s vaccination strategy in Africa.  Small pox was eliminated as an active disease threat.  I didn’t expect another such advance in my lifetime. 

Millions of people have benefitted. 

PIP Implants: Regulating Safety, the role of FDA

We’ve commented previously on the need for regulation.  In health care this is particularly the case because of the consequences.

The recent and ongoing breast implant problems from Poly Implant Prosthese (PIP) devices could well have been a major issue in the U.S. but for the FDA taking seriously it’s mandate to assess the safety of medical devices.

The now-defunct PIP was recently found to have sold implants made with industrial-grade silicone to some 300,000 women worldwide, sparking a global health scare. France’s government instructed 30,000 French women to have their implants replaced due to a high rupture rate, and the country’s health minister has called for Mas to answer for the actions of a “shady business.”

In the United States, where the FDA had banned all silicone implants from 1992-2006, PIP sold a line of saline-filled implants starting in 1996. The business accounted for up to 40 percent of its revenue, according to company securities filings. McGhan’s MediCor signed on to distribute the products in 1999, but a year later the Food and Drug Administration (FDA) conducted a new review of the devices and decided there wasn’t enough data to show they were safe.

The agency then sent an inspector to PIP’s plant in France, who found multiple violations of accepted manufacturing practices and determined the products to be “adulterated,” Reuters has reported.

Medicynical Note:  Read the entire article to get a sense of the aggressive marketing of these devices.  When money is involved people do funny things. 

Health Care Cost’s Moderating? Good News?

The U.S. leads the world in health care spending per-capita.  We spend over 2.5 trillion dollars a year (over 8,000/person) on medical expenses but still have 50 million people lacking health insurance and assured access to care—I don’t count “free” ER access as assured care.  This is one and a half to two times the expenditures of other industrialized countries.

We’ve an approach to health care that’s become unaffordable to most people.  Our country leads the world in bankruptcy due to medical expenses.  To tell the truth such a category is unheard of in other industrialized countries. 

One can cautiously take the recent news that health expenses are “only” increasing at the rate of inflation as progress in gaining control over these expenditures:

Still, the increases for 2010 and 2009 were the lowest measured in 51 years. And health care as a share of the economy leveled off at 17.9 percent, the first time in a decade there’s been no growth.

But:

The main reason for the slowdown was that Americans were more frugal in their use of health care, from postponing elective surgery to using generic drugs and thinking twice about that late-night visit to the emergency room.

Medicynical Note:  After increasing at multiples of inflation for years, health care spending seems to have finally become unaffordable, thanks to increasing  deductibles, co-pays, inadequate coverage  and lack of coverage for over 50 million citizens. 

In these hard economic times we’ve proven that rationing by ability to pay works.  It’s however a blunt instrument.  People lacking resources cut back on care, whether it’s really needed or not.  We may lose a few but then we’re saving money.

Progress?  No.  Rational?  No.